PRESS RELEASE published on 05/15/2025 at 07:00, 1 year 1 month ago Relief Therapeutics Publishes 2025 Annual General Meeting Agenda Relief Therapeutics announces agenda for its 2025 Annual General Meeting featuring key resolutions and re-elections. Meeting scheduled for June 12 in Geneva, Switzerland Shareholders Switzerland Relief Therapeutics Agenda 2025 Annual General Meeting
BRIEF published on 04/10/2025 at 07:05, 1 year 2 months ago Relief Therapeutics Announces 2024 Financial Results and Strategic Progress Biopharmaceutical Relief Therapeutics Rare Diseases 2024 Financial Results Pipeline Progress
BRIEF published on 04/10/2025 at 07:05, 1 year 2 months ago Relief Therapeutics annonce ses résultats financiers et ses progrès stratégiques pour 2024 Biopharmaceutique Maladies Rares THÉRAPEUTIQUE DE SECOURS Résultats Financiers 2024 Progrès Du Pipeline
PRESS RELEASE published on 04/10/2025 at 07:00, 1 year 2 months ago Relief Therapeutics Reports 2024 Financial Results and Provides Corporate Update Relief Therapeutics reports 2024 financial results and provides a corporate update, emphasizing operational achievements, pipeline momentum, and strengthened financial position Biopharmaceutical Corporate Update Relief Therapeutics Rare Diseases 2024 Financial Results
BRIEF published on 03/06/2025 at 07:05, 1 year 4 months ago Relief Therapeutics Ends Merger Discussions with Renexxion Shareholder Value Relief Therapeutics Strategic Objectives Renexxion Merger Termination
BRIEF published on 03/06/2025 at 07:05, 1 year 4 months ago Relief Therapeutics met fin aux discussions de fusion avec Renexxion Valeur Actionnariale Objectifs Stratégiques THÉRAPEUTIQUE DE SECOURS Renexxion Fin De La Fusion
PRESS RELEASE published on 03/06/2025 at 07:00, 1 year 4 months ago Relief Therapeutics Announces Conclusion of Merger Discussions with Renexxion Relief Therapeutics terminates merger discussions with Renexxion after failing to meet key conditions. Company remains well-positioned with robust pipeline and cash reserves Relief Therapeutics Cash Reserves Therapeutic Pipeline Renexxion Merger Discussions
BRIEF published on 02/11/2025 at 07:05, 1 year 4 months ago European Patent Office Grants Relief Therapeutics Patent for RLF-TD011 Biopharmaceuticals Relief Therapeutics RLF-TD011 European Patent Epidermolysis Bullosa
BRIEF published on 02/11/2025 at 07:05, 1 year 4 months ago L'Office européen des brevets accorde un brevet thérapeutique de secours pour le RLF-TD011 Produits Biopharmaceutiques THÉRAPEUTIQUE DE SECOURS RLF-TD011 Brevet Européen Epidermolyse Bulleuse
PRESS RELEASE published on 02/11/2025 at 07:00, 1 year 4 months ago Relief Therapeutics Announces European Patent Office Decision to Grant Patent for RLF-TD011 Relief Therapeutics obtains European Patent Office grant for RLF-TD011, securing patent protection for epidermolysis bullosa treatment. Company advances wound care solution Relief Therapeutics European Patent Office Epidermolysis Bullosa Wound Treatment RLD-TD011
Published on 07/09/2026 at 13:35, 10 minutes ago Silver X Delivers Record Quarterly Production During the Second Quarter of 2026
Published on 07/09/2026 at 13:30, 15 minutes ago Stillwater Critical Minerals Expands 2026 Exploration Program and Provides Project Update
Published on 07/09/2026 at 13:00, 45 minutes ago Evergold Mobilizes Drill to Golden Lion and Completes MobileMT Airborne Geophysical Survey, Toodoggone District, Northern BC
Published on 07/09/2026 at 13:00, 45 minutes ago Jaguar Mining Reports Commencement of Directional Drilling Program at Pilar Gold Mine, Minas Gerais, Brazil
Published on 07/09/2026 at 13:00, 45 minutes ago ATHA Energy Reports Widest Intersection to Date at Rib North Discovery with 37 m of Composite Uranium Mineralization in Ribn-DD-003 – Multiple Drillholes Demonstrating Continuity of Uranium Mineralization
Published on 07/09/2026 at 12:35, 1 hour 9 minutes ago Cognizant to scale to 5,000 Frontier Certified Engineers and 10,000 Frontier Business Operators
Published on 07/09/2026 at 12:30, 1 hour 15 minutes ago Immunic to Participate in Investor Conferences in July
Published on 07/09/2026 at 12:16, 1 hour 28 minutes ago Phase III GRAPPA trial supports ATLG (Grafalon®) as standard of care in matched unrelated donor stem cell transplantation
Published on 07/09/2026 at 07:30, 6 hours 15 minutes ago Half-year liquidity contract statement June 30, 2026
Published on 07/09/2026 at 07:30, 6 hours 15 minutes ago Half-year liquidity contract statement June 30, 2026
Published on 07/08/2026 at 20:00, 17 hours 45 minutes ago ALTAREA - INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
